drugset / Trial / NCT06384807
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Timeline
- Start
- 2024-04-22
- Primary completion
- 2028-02
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHV-1510 | Unknown | — | — |
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |